Nature Communications (Nov 2018)
Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections
- Mania Ackermann,
- Henning Kempf,
- Miriam Hetzel,
- Christina Hesse,
- Anna Rafiei Hashtchin,
- Kerstin Brinkert,
- Juliane Wilhelmine Schott,
- Kathrin Haake,
- Mark Philipp Kühnel,
- Silke Glage,
- Constanca Figueiredo,
- Danny Jonigk,
- Katherina Sewald,
- Axel Schambach,
- Sabine Wronski,
- Thomas Moritz,
- Ulrich Martin,
- Robert Zweigerdt,
- Antje Munder,
- Nico Lachmann
Affiliations
- Mania Ackermann
- JRG Translational Hematology of Congenital Diseases, Hannover Medical School
- Henning Kempf
- Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, REBIRTH Cluster of Excellence, Hannover Medical School
- Miriam Hetzel
- Institute of Experimental Hematology, REBIRTH Cluster of Excellence, Hannover Medical School
- Christina Hesse
- Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), REBIRTH Cluster-of Excellence
- Anna Rafiei Hashtchin
- JRG Translational Hematology of Congenital Diseases, Hannover Medical School
- Kerstin Brinkert
- Clinical Research Group ‘Cystic Fibrosis’, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School
- Juliane Wilhelmine Schott
- Institute of Experimental Hematology, REBIRTH Cluster of Excellence, Hannover Medical School
- Kathrin Haake
- JRG Translational Hematology of Congenital Diseases, Hannover Medical School
- Mark Philipp Kühnel
- Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), German Center for Lung Research
- Silke Glage
- Institute of Laboratory Animal Science and Central Animal Facility, Hannover Medical School
- Constanca Figueiredo
- Institute for Transfusion Medicine, Hannover Medical School
- Danny Jonigk
- Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), German Center for Lung Research
- Katherina Sewald
- Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), REBIRTH Cluster-of Excellence
- Axel Schambach
- Institute of Experimental Hematology, REBIRTH Cluster of Excellence, Hannover Medical School
- Sabine Wronski
- Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), REBIRTH Cluster-of Excellence
- Thomas Moritz
- Institute of Experimental Hematology, REBIRTH Cluster of Excellence, Hannover Medical School
- Ulrich Martin
- Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, REBIRTH Cluster of Excellence, Hannover Medical School
- Robert Zweigerdt
- Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, REBIRTH Cluster of Excellence, Hannover Medical School
- Antje Munder
- Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), German Center for Lung Research
- Nico Lachmann
- JRG Translational Hematology of Congenital Diseases, Hannover Medical School
- DOI
- https://doi.org/10.1038/s41467-018-07570-7
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 13
Abstract
Pulmonary infections constitute a substantial health problem worldwide. Here the authors show that phagocytes similar to primitive macrophages can be generated from human induced pluripotent stem cells, by the use of industry-compatible, stirred-tank bioreactors, and applied as a cell-based therapy to treat acute bacterial infections in mice.
